Novo Nordisk buys US and Canadian rights to Macrilen for $145 million

31 October 2018

Signalling its intention to grow its biopharma business in the USA, Danish diabetes giant Novo Nordisk (NOV: N) has bought the US and Canadian rights to Macrilen (macimorelin), from Strongbridge Biopharma.

Macrilen is the first and only US Food and Drug Administration-approved oral growth hormone receptor indicated for the diagnosis of adult growth hormone deficiency (AGHD), a rare endocrine disorder.

The product was approved by the US FDA in December 2017 and was launched in the USA in July 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK